Please login to the form below

Not currently logged in
Email:
Password:

EC approves drugs for diabetes and Crohn’s disease

Takeda’s Entyvio and Boehringer/Lilly’s Jardiance get green light
EU flag

The European Commission (EC) has approved Takeda's Entyvio (vedolizumab) to treat adults with ulcerative colitis and Crohn's disease and Boehringer Ingelheim/Lilly's Jardiance (empagliflozin), which adds to the growing list of treatments for type 2 diabetes.

The approvals cover the European Union and come two months after scientific advisers at the European Medicines Agency (EMA) backed both products, and the same week that Entyvio was approved by the US FDA.

As per this recommendation, Entyvio is approved to treat patients with ulcerative colitis and Crohn's disease who cannot tolerate or who respond poorly to conventional therapy or a tumour necrosis factor (TNF) antagonist such as J&J's Remicade (infliximab)

Both conditions are types of inflammatory bowel disease and are thought to affect more than two million people in Europe, potentially offering a large market to Takeda despite the limited approval.

Entyvio - a humanised monoclonal antibody - marks Takeda's first step into inflammatory bowel disease, and has been cited by the company as a key part of its growth plans.

Data from late-stage trials back these ambitions, demonstrating the drug's effectiveness in improving remission rates.

Meanwhile, Boehringer and Lilly also celebrated obtaining EU marketing authorisation for their diabetes treatment Jardiance – the latest in a new class of drugs called SGLT-2 inhibitors to win approval.

These treatments work independently of insulin by blocking the re-absorption of glucose into the bloodstream, causing it to be removed via the urine. 

SGLT-2 inhibitors already on the market in Europe include Johnson & Johnson's Invokana (canagliflozin) and AstraZeneca's Forxiga (dapagliflozin).

Both these products are also available as combination treatments with metformin in versions called Vokanamet (Invokana and metformin) and Xigduo (Forxiga and metformin).

The EC approval gives Boehringer and Lilly and a chance to catch up on their rivals and a combination of Jardiance and metformin is also in the works.

Article by
Thomas Meek

28th May 2014

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics